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Excessive accumulation of pro-oxidant metals, observed 
in affected brain regions, has consistently been implicated as a 
contributor to the brain pathology including neurodegenerative 
diseases and acute injuries such as stroke. Furthermore, the 
potential interactions between metal toxicity and other 
commonly associated etiological factors, such as 
misfolding/aggregation of amyloidogenic proteins or genomic 
damage, are poorly understood. Decades of research provide 
compelling evidence implicating metal overload in neurological 
diseases and stroke. However, the utility of metal toxicity as a 
therapeutic target is controversial, possibly due to a lack of 
comprehensive understanding of metal dyshomeostasis-
mediated neuronal pathology. In this article, we discuss the 
current understanding of metal toxicity and the challenges 
associated with metal-targeted therapies.
Metal accumulation in the brain, a common phenomenon in 
the pathophysiology of neurodegenerative diseases and 
stroke 
The optimum levels of trace elements and their 
homeostasis in individual organs are essential for maintaining 
vital functions. Nutritional deficiencies and metabolic disorders 
exhibit potential cause-and-effect relationship in many 
pathological conditions. Although many metal ions, some at 
trace levels, are essential for life, excess accumulation can be 
highly toxic and possibly fatal. Neurodegeneration is believed to 
be the most common manifestation of metal toxicity. For 
example, etiological link between abnormal metal accumulation 
in the brain and aging or various neurological disorders, 
including Alzheimer’s Disease (AD), Parkinson’s Disease (PD), 
Amyotrophic Lateral Sclerosis (ALS), Wilson’s Disease (WD), 
and stroke was observed [1-7]. Acute metal toxicity is 
implicated in stroke and certain conditions that result from 
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hereditary defects in the regulation of metal homeostasis. For 
example, the dysregulation of metal ions due to the acute release 
of free iron (Fe) following hemorrhagic stroke causes massive 
neuronal injury [3,8]. Furthermore, neurotoxicity from acute
increase in the level of zinc (Zn) and other transition metals may 
play a critical role after ischemic focal brain injury [9].
Environmental/dietary sources versus genetic factors –Fe
accumulation in the brain during hemorrhagic stroke is thought 
to be due to the breakdown of hemoglobin. However, the source 
and the mechanisms of accumulation of other metals in the 
brain are unclear, because only in a few cases, this could be 
linked to dietary or occupational exposures [10]. It is generally 
believed that both environmental and genetic factors are 
responsible for abnormal metal accumulation in neurological 
conditions. Environmental factors include malnutrition, 
contaminated water, food, and beverages, 
occupational/hazardous exposures, and medical procedures. 
Individual metal ions have specific physiological function(s) as
co-factors for many essential vitamins and proteins. High 
incidences of neurodegenerative diseases, such as ALS, AD, 
and PD, have been observed in employees in the automobile and 
paint industries and in other metal-utilizing factories [11,12]. 
Recent studies suggest that various genetic factors predispose 
neurons to enhanced metal toxicity. These include alterations in 
metal mobility or uptake across the blood-brain barrier and 
metal storage proteins in the brain, including lactoferrin and 
ferritin/transferrin. Friedreich’s ataxia, a genetic disorder of Fe 
metabolism, is caused by insufficient level of the Fe chaperone,
frataxin, which leads to dysregulation of Fe trafficking in 
mitochondria and to mitochondrial genome damage by Reactive 
Oxygen Species (ROS) [13-16]. Similarly, abnormal Fe 
metabolism is responsible for the etiopathogenesis of hereditary 
ferritinopathy [17]. Another well-known, autosomal recessive 
disorder, Wilson’s disease, arises from a lethal mutation in the 
ATP7B gene, which encodes a copper (Cu) transporter, leading 
to supra-physiological, accumulation of free Cu in the brain and 
liver [18]. Aging is another contributor to chronic accumulation 
of brain metals [19]. Fe(III), Cu(II), and Zn(II) ions play critical 
roles in the gradual progression of AD and PD in an age-
dependent manner by stabilizing misfolded amyloid beta sheets 
[20,21].
Thus, complex interactions between genetic 
predisposition and environmental/dietary influences appear to 
induce accumulation of free metal ions in the brain. 
Molecular basis of metal toxicity
As schematically represented in Figure 1, metal dyshomeostasis 
is deleterious to human cells. The intracellular and extracellular 
levels of metals are tightly regulated through a complex 
network. Excessive concentration of non-sequestered metal salts 
could cause cellular toxicity and pathological damage. In 
addition to altering the membrane potential, particularly in 
neurons, metal ions can bind to and affect the activity of 
proteins/enzymes and nucleic acid, which may cause 
cytotoxicity. In addition, the major cause of oxidative toxicity 
from transition metals is the generation of ROS, the most 
pervasive oxidant in cells [22-25]. In addition, many heavy 
metals, such as cadmium and lead, are also pro-oxidant and 
highly toxic. These could cause membrane depolarization by 
blocking calcium-ion influx and cell death [26-28]. 
Individual metal accumulation versus metal homeostatic 
imbalance – As already stated, metal content is tightly 
regulated under physiological conditions in the normal brain 
through sequestration by storage proteins (e.g., ferritin, 
transferrin, and ceruloplasmin). The stored metals are released 
only in response to metabolic needs. Abnormal sequestration 
leading to metal overload is a common feature of neuronal 
pathologies; remarkably, studies have revealed unique charge-
dependent changes in brain metal homeostasis with the 
progression of disease severity in AD and PD [29]. For 
example, the level of divalent Fe(II) or Cu(II) increases in the 
brain during the early phase of AD [30]. Interestingly, in AD 
and PD cases with no evident dietary metal exposure, the 
overall brain metal burden was found unaltered; instead, there is 
a charge-dependent redistribution of specific metals in the 
affected brain regions. For example, increase in Fe in PD 
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patients, is simultaneously associated with decrease in Zn [5]. 
This may imply that the impact of an increase or decrease of an 
individual metal is not restricted to that metal alone, but causes 
a more dramatic overall homeostatic imbalance of metals, 
presumably due to loss of regulation of metals across cell 
membranes. This may be important for formulating metal 
chelation therapy, which should include supplementation of the 
depleted metal, in addition to chelating the increased metal ions.
It is noteworthy that in contrast to AD and PD, for other 
neurological disorders and stroke, there are limited data 
regarding trace metal homeostasis or inter-elemental 
relationships in the brain. A comprehensive database for the 
pathological dyshomeostasis of metals is critical for early 
diagnosis and for improving our understanding of the role of 
metals in neurotoxicity.
Metals cause genomic damage directly and via generation of 
ROS –Oxidative genomic damage is the most common type of 
damage caused by pro-oxidant metals due to ROS generated via
Fenton and Haber-Weiss reactions. In addition, some heavy 
metals including essential metals produce DNA damage via 
direct binding and cause strand breaks [31,32]. Both ROS and 
metals induce a multitude of oxidative modifications in DNA 
bases and sugar moieties, including DNA strand breaks. 
Persistent accumulation of this damage could lead to secondary 
double-strand breaks, which are the most toxic genomic damage 
[33,34]. 
Inhibition of genome repair machinery by metals–While
marked increase in genomic damage is observed in a majority of 
neurodegenerative diseases, the neurons also show decreased 
ability to repair the damage [35,36]. Moreover, the lack of a 
direct correlation between repair deficiencies and expression of 
repair enzymes suggests the involvement of additional 
mechanisms. Repair defects induced by heavy metals have been
commonly attributed to their direct binding to DNA, which 
interferes with the repair machinery’s ability for genome 
damage scanning/recognition and repair [37-39]. We recently 
showed that physiological levels of iron and copper salts 
inhibited the NEIL1/2 enzymes, two key components of the 
oxidized DNA base repair machinery (via base excision repair 
or BER) [6,37,40-43]. Inhibition of these enzymes is due to 
metal binding to themselves rather than to DNA, which involves 
reversible oxidation of cysteine residues in the enzymes. 
Furthermore, these metal ions disrupt protein-protein 
interactions during BER, which is critical for coordinating the 
complete repair at the chromatin level. Thus our studies, in 
contrast to previous observations, suggest that metal-induced 
defects in genome repair is caused by direct binding of redox 
metals to specific repair proteins, which affects their redox state 
and structure/function. It is likely that persistent accumulation 
of genomic damage could elicit inflammatory responses (i.e., 
microglia activation), further contributing to neuronal 
dysfunctions [6].
Metal-targeted therapies: Past and current challenges
Metal chelation therapy has been explored as a strategy to 
eliminate excess metal ions from the body. This treatment has 
had mixed success due to challenges intrinsically associated 
with chelation and the inherent complexity of metal dynamics in 
the body. 
Some metal chelators successfully reduce metal build-up 
in animals and in in vitro models. Although chelators were 
shown to reduce metal accumulation in the humans in clinical 
trials, several challenges prevented their broad application.
First, most available chelating compounds fail to cross the 
Blood-Brain Barrier (BBB). Desferrioxamine B (DB), an iron 
chelator, was one of the first metal chelators used in AD 
patients, where it caused a significant decline in amyloid plaque 
levels and decreased the cognition deterioration rate [44]. 
However, DB caused anemia over time [45]. Clioquinol (CQ), 
another metal chelator, was reported to restore metal 
homoestasis in several animal models of neurodegeneration and 
in AD patients [29,45,46]. CQ efficiently crosses the BBB, 
preferentially binds Cu(II) and Zn(II), and inhibits amyloid-ȕ
deposition [47]. However, a CQ derivative, 8-hydroxyquinoline 
(8-OHQ; also named PBT2; Prana Biotechnology), failed in a 
phase III trial due to non-VLJQLILFDQW FOHDUDQFH RI ȕ-amyloid 
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plaques in patients with mild AD (Product News, J Gerontol. 
Nurs. 40, 5-6, 2004).
Magnetic resonance imaging data from phase II clinical 
trials indicated that deferiprone (DFP), a metal chelator used to 
treat thalassemia patients, significantly decreases Fe levels in 
the Substantia Nigra (SN) in patients with early or late PD [48]. 
However, after 24-month treatment, the chelation benefits of 
DFP disappeared, and Fe deposition reappeared in the SN. 
These data suggest that a readjusted treatment time should be 
considered for long-term benefits [48].  In contrast to other 
chemical chelators, DFP alleviates Fe accumulation by donating 
chelated Fe to unsaturated transferrin, and allows balanced 
retention and chemical redistribution of Fe in the body [49]. 
In an investigation using a mouse stroke model, the 
ferrous chelator 2,2'-bipyridine was shown to be effective in 
reducing brain injury following Intra Cerebral Hemorrhage 
[ICH] and ischemia [50,51]. Although this chelator appears to 
be promising for preventing brain injury after stroke, recent 
reports suggest that bipyridine does not prevent iron-induced 
damage in three ICH rat models [52]. Thus, its efficacy as a 
therapeutic agent remains unclear.
Natural metal chelators, including curcuminoids and 
catechins, are predominant components of the rural Asian diet 
and are believed to be highly beneficial for combating 
neurotoxicity [43]. Curcumin is the most popular curcuminoid, 
present in turmeric and known for its unique flavor, has a broad 
spectrum of pharmacological properties. In recent years, this 
traditional Indian spice has gained attention for its ability to 
bind metals and protect neurons. For example, curcumin 
protects hippocampal neurons against Pb- and Cd-induced lipid 
peroxidation [53]. 
Catechins comprise another class of potential metal 
chelators commonly found in green tea, berries, cocoa, and 
onions. Epigallo Catechingallate (EGCG) is a common catechin
explored for its chemo-protective and neuroprotective functions. 
Chemically, EGCG possesses iron-chelating properties, by 
possibly neutralization of ferric iron and  formation of redox-
inactive iron in neuronal cells [1]. Although the therapeutic 
potential of natural compounds for acute metal toxicity needs 
further investigation, their inclusion in a balanced dietcould 
provide a cost-effective strategy for reducing the oxidative 
burden in patients with neurodegenerative disorders or stroke.
Challenges and future perspectives
There is compelling evidence linking metal toxicity to neuronal 
dysfunction. In addition, there has been an enormous increase in 
our understanding of the molecular basis of metal neurotoxicity. 
Nonetheless, current metal-targeted therapeutic approaches 
remain to be proven effective. Further, antioxidant therapies 
have not been as effective as expected. This underscores the 
need to explore new approaches to unraveling the bases for 
neuronal pathobiology. Current molecular studies have not 
effectively improved our ability to rationally apply metal-
targeting-based therapeutic approaches. We suggest that recent 
basic discoveries on metal biochemistry may help develop new 
approaches for enhancing efficacy of metal chelation therapy.
For instance, intracellular metal dyshomeostasis involving auto-
depletion of specific metal ions is a common occurrence after 
individual metal overload; thus, metal chelation strategies 
should include supplementation of depleted metals.
Furthermore, because of  reversible oxidation of cysteine 
residues in various proteins, including the key genome repair 
enzymes NEIL1 and NEIL2 by pro-oxidant metals [37,40], 
metal chelation could be combined with specific reducing 
factors [6,29,43]. Thus, the recent advances discussed here
underscore the need to revisit the role of metal toxicity in
neurological diseases and stroke in order to develop new
therapeutic strategy.
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Figure: 1
 
 
Figure 1: Molecular basis for metal neurotoxicity and its 
potential as a therapeutic target. Studies suggest a charge-based 
dyshomeostasis of metals in neurons affected by degenerative 
diseases. Typically, trivalent metals increase in late-stage AD, 
whereas divalent metal ions increase in early AD. The increase 
in metal ions could reversibly inhibit DNA repair enzymes, 
inducing genomic damage. Metal chelation therapy should 
address these challenges based on recent molecular 
understanding of the phenomenon.
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